Early Prediction of Alzheimer’s Disease by Using BloodBased Biomarkers: A Comprehensive Review
Abstract:
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by the slow progression of pathological processes
that lead to dementia. The diagnosis of AD is traditionally
associated with highly invasive and costly procedures such as
cerebrospinal fluid (CSF) analysis or expensive neuroimaging
techniques like PET scans—methods that are usually
inaccessible, costly, and unsuitable for large-scale population
screening. Recently, there has been a rapid increase in studies
demonstrating the ability of blood-based biomarkers (BBBs)
to detect pathological changes in the brain. These include
markers of abnormal protein metabolism, glial cell activation,
and neuronal damage. This review aims to discuss the current
literature data on the role of BBBs in the differential diagnosis
of AD and other dementias. Particular attention is paid to the
assessment of diagnostic accuracy and potential clinical
applications of such biomarkers as Aâ 42/ Aâ 40 plasma
amyloid beta ratio, phosphorylated tau181, phosphorylated